Neurol. praxi. 2009;10(5):305-308

New drugs era in treating multiple sclerosis

MUDr. Marta Vachová
MS centrum, Neurologické oddělení, Krajská zdravotní a.s., Nemocnice Teplice o.z

Contemporary therapeutic approaches for treating of Multiple sclerosis have their limitation. The efficacy is not 100 % and long lasting

invasive application have troubles, which lead to less therapeutic effect. This is the reason for developing new ways, schemes and



methods: Some of them were blind and did not fulfil expectations. Other new medications are very effective, but have serious adverse

events. The article introduces new medications, which came through all phases of clinical testing to the registration or phase III studies

have been just ending. This involves five oral disease-modifying agents and monoclonal antibodies group which represents another

big expectation.

Keywords: multiple sclerosis, cladribin, fingolimod, fumarate, laquinimod, teriflunamide, monoclonal antibodies.

Published: December 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vachová M. New drugs era in treating multiple sclerosis. Neurol. praxi. 2009;10(5):305-308.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Coyle PK, Hammad MA. Atlas of Multiple Sclerosis. London: Science Press Ltd. 2003: 86 s.
    2. Friese MA, Montalban X, Willcox N, Bell JI, Martin R, Fugger L. The value of animal models for drug development in multiple sclerosis. Brain 2006; 129(8): 1940-1952. Go to original source... Go to PubMed...
    3. Havrdová E. Neuroimunologie. Maxdorf Praha 2001: 451 s.
    4. Kleischnitz C, Meuth GS, Wiendl H. The Trials and Errors in MS Therapy. Int MSJ 2008; 15: 79-90.
    5. Lee DH, Linker RA, Gold R. Spotlight on Fumarates. Int MSJ 2008; 15: 12-18.
    6. Merck Serono. Merck Seronoś Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate in Two Year Phase III Pivotal Trial. News Release. Geneva 23Jan2009.
    7. Novartis. First phase III results for FTY720, a novel oral therapy for MS, show superior efficacy compared to interferon beta-1a. Media release. Basel 12Dec2008.
    8. Schippling S, Martin R. Spotlight on Anti-CD25: Daclizumab in MS. Int MSJ 2008; 15: 94-98.
    9. Simpson BS, Coles AJ. Ratinale for cytotoxin Monoclonal Antibodies in MS, Int MSJ 2007; 14: 48-56.
    10. Tallantyre E, Evangelou N, Constantinescu CS. Spotlight on teriflunamide. Int MSJ 2008; 15: 62-68.
    11. Waubant E. Spotlight on Anti-CD20. Int MSJ 2008; 15: 19-25.
    12. Weber MS, Stuve O, Neuhaus O, Hartung HP, Zamvil SS. Spotlight on Statins. Int MSJ 2007; 14: 93-97.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.